The little-known pharmaceutical company, Emergent BioSolutions, was a key to Johnson & Johnson’s plan to deliver 100 million doses of its vaccine to the U.S. by the end of May.
The little-known pharmaceutical company, Emergent BioSolutions, was a key to Johnson & Johnson’s plan to deliver 100 million doses of its vaccine to the U.S. by the end of May.